Keywords
Asthma
Efficacy
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the efficiency of biological therapies with monoclonal antibodies in patients with severe asthma. Methods: This study is an integrative review and was carried out by evaluating the literature available on the PubMed Central platform with the following MeSH terms: Monoclonal Antibodies, and Asthma, with the objective of answering whether the effectiveness of biological therapies with monoclonal antibodies in the treatment of severe asthma is superior to conventional treatments. Initially, 1339 full articles published between 2018 and 2023, in English, Portuguese and Spanish, were selected. After inclusion criteria, duplicate articles, abstracts and those that did not meet the selection criteria were removed, leaving 26 articles that were included in this review. Results: The benefit of antibodies such as benralizumab, reslizumab, mepolizumab, dupilimab and omalizumab was evidenced, as they are efficient in reducing severe asthma exacerbations when compared with inhaled and oral corticosteroids in the treatment of these patients. Final considerations: Although further studies on the subject are still needed, improvements in the control of severe asthma with monoclonal antibodies, using validated questionnaires, were significant, compared to usual treatments, in most of the evaluated studies.
References
ADACHI M, et al. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan. Respiratory Medicine, 2018; 41, 56-63.
AGACHE I, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5): 1023-1042.
BERGANTINI L, et al. Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab. Int Arch Allergy Immunol. 2020; 181(10):746-753.
BLEECKER ER, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. The Lancet. 2016, 388(10056):2115-2127.
BOURDIN A, et al. dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline. Respir Med. 2022; 202:106938.
BUSSE WW, et al. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol, 2020;125(5):565-576.e1.
CASALE T, et al. Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities. Ann Allergy Asthma Immunol. 2021; 127(3): 354-362.
CHARLES D, et al. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis. Wiley, 2022; 52(5), 616-627.
COLOMBO GL, et al. omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review. Ther Adv Respir Dis. 2019;13:1753466619841350.
CORREN J, et al. dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Annals of Allergy, Asthma & Immunology, 2019; 122(1), 41-49.
DOROUDCHI A, et al. Asthma biologics: Comparing trial designs, patient cohorts and study results. Ann Allergy Asthma Immunol. 2020;124(1):44-56.
FAULKNER KM, et al. 'Real-world' effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert Rev Clin Immunol. 2021; 17(1): 73-83.
FITZGERALD JM, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2016; 388(10056): 2128-2141.
IBRAHIM H, et al. The effectiveness of Reslizumab in severe asthma treatment: a real-world experience. Respiratory Research, 2019; 20(1), 1-5.
KARDAS G, et al. Biological therapies of severe asthma and their possible effects on airway remodeling. Frontiers in Immunology, 2020; 11: 1134.
KARDAS G, et al. Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives. Frontiers in Immunology, 2022; 13: 983852.
KAWAMATAWONG T, et al. Long-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: A real-life experience. Asian Pacific Journal of Allergy and Immunology, 2018; 36(4), 238-243.
KELSEN SG, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. Journal of allergy and clinical immunology, 2021;148(3), 790-798.
LIU Y, et al. Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma. Allergy Asthma Proc, 2018;39(5):332-337.
MACDONALD KM, et al. Short-and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert review of clinical immunology, 2019; 15(5), 553-569.
MCGREGOR MC, et al. Role of Biologics in Asthma. American Journal of Respiratory and Critical Care Medicine, 2018; 199(4), 433-445.
NAGASE H, et al. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergology International, 2023; 72(1), 11-23.
PADILLA-GALO A, et al. Real‐life cost‐efectiveness of benralizumab in patients with severe asthma. Respiratory Research, 2021;22(1), 163.
PAPI A, et al. dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma.Allergy. 2023;78(1):233-243.
PFEFFER PE, et al. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both. Allergy. 2023;78(7):1934-1948.
RAMONELL RP e IFTIKHAR IH. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis. Lung, 2020;198(1):95-103.
SHAFIEI-JAHANI P, et al. CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation. Mucosal Immunol. 2021;14(4):899-911.
SOONG W, et al. omalizumab response in patients with asthma by number and type of allergen. Ann Allergy Asthma Immunol. 2021;127(2):223-231.
STANLEY J, et al. Treatment Benefit with omalizumab in Children by Indicators of Asthma Severity. J Allergy Clin Immunol Pract, 2020; 8(8), 2673-2680.
TORRES-DUQUE CA, et al. Real‐world efectiveness of omalizumab for severe allergic asthma treatment in Colombia. BMC Pulmonary Medicine, 2022; 22(1), 1-10.